There is no cure for Huntington's disease, and every approved drug treats symptoms only. But Huntington's is caused by one known gene, which makes it one of the most targetable brain diseases. Our view: the cure will come from lowering the toxic huntingtin protein early, before symptoms, with a one-time gene therapy or a daily pill.
This is Cure Checker's editorial assessment of published evidence, not medical advice. Treatment and genetic-testing decisions belong with a neurologist and a genetic counselor, ideally at an HDSA Center of Excellence.
Please read first. This is an AI-generated hypothesis, written by Cure Checker's AI from published research. It is speculation, not an established finding. It is not a recommendation, not a prediction that a cure exists, and not medical advice. No doctors or scientists have reviewed it, and it may be wrong. Never start, stop, change or delay any treatment because of it. Talk with your neurologist or genetic counselor.
Could a drug that slows repeat growth, which does not yet exist for people, keep most vulnerable brain cells below the danger zone if started in gene carriers years before symptoms? And would adding huntingtin lowering protect them longer than either alone, judged by spinal-fluid markers and brain scans?
What would prove it wrong: if slowing repeat growth in people does not change nerve-damage markers or brain shrinkage over several years, or if brain cells die without passing the repeat threshold.
Hypothesis written October 6, 2026. Cure Checker's AI will revisit it when major new evidence appears.
Newest first. Updated each morning as results, trial launches and papers are published.
Researchers delivered a small RNA that lowers MSH3, a gene that helps the Huntington's CAG repeat grow, using a virus aimed at the brain cells most affected. It cut MSH3 messenger RNA by 48 to 94% in monkey brain cells and reduced repeat growth by up to 46% in Huntington's mice. A computer model built on patient data predicted slower progression, but that is a prediction, not a result in people. Early preclinical work.
In human Huntington's brain tissue, nerve cells in the cortex showed the same sequence of changes as striatal cells, with toxicity starting at about 150 CAG repeats, and the extent of repeat growth varied up to 20-fold between cell types. It supports repeat growth as a target for future drugs. Lab study of donated tissue, not a treatment test.
Presented at the European Huntington's Disease Network congress and reported by STAT. At the highest dose, mutant huntingtin in spinal fluid fell by about 60 to 64% on average, depending on the test. The company calls safety encouraging, but full safety data and lower-dose results were not given. Lowering the protein is not proof the drug slows the disease; Alnylam plans a placebo-controlled study next year. Company data, not peer-reviewed.
In 247 people on placebo in the PROOF-HD trial, those taking dopamine-blocking medicines (antipsychotics or VMAT2 inhibitors) declined faster on function and thinking scores than those who were not (at week 52, 0.85 points on the function scale, p < 0.0001). This was an after-the-fact analysis, and sicker people may be more likely to take these drugs. Some authors work for Prilenia, which makes pridopidine. It does not mean people should stop medicines on their own.
A CRISPR tool that nicks DNA shortened the CAG repeat in patient-derived brain cells and, after injection into the brain of a Huntington's mouse model, in more than half of striatal neurons. The mice had fewer protein clumps and moved better. Early lab and mouse work, not tested in people.
The main goal was not met: in 139 people, the drop in chorea (involuntary movements) on 600 mg/day was not statistically significant versus placebo (p = 0.096). A planned analysis of people not taking antipsychotics did reach significance. Generally well tolerated; the most common side effect was slow heartbeat. The drug maker funded it and says a Phase 3 is planned.
Slowed progression by 44% compared with matched outside controls, a difference that was not statistically significant. The benefit is smaller than in the analysis a year earlier, which raises questions about how long it lasts. The FDA is now reviewing the application.
A 1.59-point cUHDRS benefit compared with an external natural-history control, up to 62% lower mutant huntingtin in blood, and good tolerability.
First approval application for a Huntington's gene therapy, seeking U.S. accelerated approval on three-year Phase 1/2 data.
Met safety and biomarker goals but showed no meaningful clinical benefit over placebo. The POINT-HD program also stopped.
A 400-person placebo-controlled confirmatory trial of the daily pill in early to mid-stage Huntington's. Recruitment began in the U.S., with EU, UK and Canada sites to follow later in 2026. The drug is not approved in the EU.
After a Type B meeting, the FDA said three-year data could be the main basis of the application, reversing its earlier request for another study.
Dose-dependent slowing on cUHDRS (52% at 10 mg, 28% at 5 mg) compared with a natural-history cohort. Novartis launched the INVEST-HD Phase 3.
Global placebo-controlled trial of the daily pill in early symptomatic Huntington's.
Withdrawn during re-examination after the EMA committee's negative opinion in July 2025.
Today's approved drugs only calm movements and mood. The new wave aims at the gene itself. Some are showing the first signs of actually slowing the disease, though these are early, small results.
Injected once into the brain to permanently lower huntingtin. At three years, the high dose showed 75% slower decline than matched outside patients, plus lower NfL. The trials were small (dozens of patients). The FDA agreed in June 2026 that these data could support accelerated approval.
At 24 months, decline slowed by 52% (10 mg) and 28% (5 mg) compared with a natural-history group. Novartis started the INVEST-HD Phase 3, aiming for about 770 people.
Lowered mutant huntingtin in blood by up to 62% and showed a 1.59-point benefit on the main Huntington's rating scale at 15 months, compared with an outside control group.
The newest of three VMAT2 drugs that calm involuntary movements. It treats a symptom and doesn't slow the disease.
The GENERATION HD2 trial met its safety and biomarker goals but didn't show meaningful benefit over placebo, so Roche ended the program.
Europe's medicines committee advised against approval in July 2025, and the company withdrew its application in November 2025 to collect more data.
| Treatment | For | What it does |
|---|---|---|
| Tetrabenazine (U.S. 2008), deutetrabenazine (2017), valbenazine (2023) | Chorea | VMAT2 inhibitors that reduce involuntary movements. They can worsen depression, so mood needs watching. |
| Antidepressants, antipsychotics | Mood, irritability, psychosis | Treat the psychiatric symptoms that often affect families most. |
| Physical, speech & occupational therapy | Everyone | Keep walking, swallowing and daily life safer for longer. |
| Genetic counseling & testing | At-risk family members | Testing is a personal choice and should always come with counseling. |
No supplement prevents or slows Huntington's. Several were tested in large trials and failed. Nutrition and exercise still matter for quality of life. We rate each by the strength of human evidence.
Small trials suggest better balance, fitness and mood. It's safe and widely recommended. Work with a therapist who knows Huntington's.
Many people with Huntington's lose weight despite eating well, and weight loss tracks with faster decline. A dietitian can help with calories and safe swallowing.
Linked to later symptom onset in observational studies. It isn't proof, but it's a healthy choice anyway.
A large trial in early Huntington's was stopped for futility.
A large Phase 3 trial (2CARE) found no slowing of decline.
Controlled trials didn't show a benefit on Huntington's symptoms.
Be careful: chorea drugs (VMAT2 inhibitors) can worsen depression and interact with other medicines. Some supplements claim to "lower huntingtin" with no evidence at all. Tell your care team about everything you take.
Centers recognized for expertise in this condition, and communities of people living with it.
Designated by the Huntington's Disease Society of America as a Center of Excellence.
Designated by the Huntington's Disease Society of America as a Center of Excellence.
Designated by the Huntington's Disease Society of America as a Center of Excellence.
Designated by the Huntington's Disease Society of America as a Center of Excellence.
Holds the French national rare-disease reference centre label for Huntington's disease, first awarded in 2004.
These are centers recognized for expertise in this condition, not a ranking, and Cure Checker does not endorse or rate any facility. Outcomes depend on the individual. Ask your doctor which center fits your situation.
You don't have to face Huntington's alone. These groups connect patients, at-risk family members and caregivers with people who understand. Most are free.
The Huntington's Disease Society of America runs more than 200 free support groups, plus Centers of Excellence and social workers.
Find support ↗The Huntington's Disease Youth Organization supports young people growing up with Huntington's in the family, worldwide and in many languages.
Get support ↗Specialist advisers, local branches and support groups across England and Wales.
Get support ↗Family services, resource centers and support groups across Canada.
Get support ↗A global network of national Huntington's associations. Use it to find the group in your country.
Find your country ↗Many family, caregiver and at-risk groups. This link searches Facebook (a login is required).
Search Facebook ↗For research news written for families in plain language, see HDBuzz. Deciding whether to take the genetic test is a big step, and HDSA and HDYO can connect you with genetic counseling first.
Before you join: support groups share experiences, not medical advice. Check anything about treatment with your doctor. Think about your privacy, especially about genetic status, because many forums are public. Never share passwords or financial details. Cure Checker isn't affiliated with these groups.
Symptom drugs vary from country to country. The U.S. has approved three chorea drugs, while Europe mainly uses one. The first disease-slowing treatments are being filed in the U.S. and UK first.
| Treatment | U.S. | EU | UK | Canada | Japan | S. Korea | China | Australia | Switz. |
|---|---|---|---|---|---|---|---|---|---|
| TetrabenazineChorea | 2008 | Yes | Yes | Yes | — | — | — | — | — |
| DeutetrabenazineChorea | 2017 | — | — | — | — | — | — | — | — |
| ValbenazineChorea | 2023 | — | — | — | — | — | — | — | — |
| PridopidineFunction | — | Withdrawn 2025 | — | — | — | — | — | — | — |
| AMT-130Gene therapy | Filed 2026 | — | Filed 2026 | — | — | — | — | — | — |
The only country with three approved chorea drugs, and the first to receive an application for a Huntington's gene therapy.
Europe relies mainly on tetrabenazine for chorea. Its regulator turned down pridopidine in 2025, and the company has withdrawn its application while it collects more data.
uniQure filed AMT-130 in the UK alongside the U.S., so the UK could be among the first countries to decide on a disease-slowing Huntington's treatment.
Huntington's is caused by a single faulty gene, HTT. A stretch of its DNA, the three letters "CAG," repeats too many times. The result is a toxic form of the huntingtin protein that slowly damages brain cells, starting in a region that controls movement and mood.
Live numbers and the newest entries from the world's main trial registries and medical databases. Most of this loads fresh each time you open the page.
Loading live data from ClinicalTrials.gov…
Loading…
Loading…
Loading…
| Medicine | Brand | FDA application | Original approval |
|---|
From Drugs@FDA via FDA's openFDA service. Some older brands are missing from FDA's open data, and newly approved drugs can take a few weeks to appear. An approval may be for a different disease than this one.
The WHO's ICTRP gathers trials from registries worldwide, including China, Japan, India, Iran, Australia and Brazil. Cochrane CENTRAL and OpenMD don't allow automated access, so they're linked here for you to search directly.
These organizations exist to help families affected by Huntington's disease pay for care and costs. Few such programs exist and some were closed when checked. Funds are limited and rules vary, so contact each one directly.
Grants toward medical bills and prescriptions, travel to appointments, groceries and gas, legal fees, counseling and IVF. Family or friends can nominate someone. Not every request can be funded.
See the program ↗The Help 4 HD Relief Fund gives emergency help with medicine, food, clothing and other necessities, only while money is in the fund. There is no application form; contact the charity.
See the program ↗Grants cover one round of IVF with embryo genetic testing once stimulation begins, so families can have children without the HD gene. Grants are awarded in yearly cycles; the 2026 cycle is closed.
See the grant ↗Small donor-funded welfare grants for home adjustments, equipment or replacing broken appliances, with set criteria. Ask the charity or your Specialist Adviser how to apply.
Read about welfare grants ↗Welfare grants for equipment or financial hardship for households with savings under £8,000, and a Short Breaks Fund toward respite breaks. Funds are limited, and the Short Breaks Fund was not taking applications when checked.
See the grants ↗Helps pay prescription copays for Huntington's medicines, or Medicare Part B premiums. The fund was listed as closed to new patients for lack of funding on October 6, 2026.
Check fund status ↗Before you apply: Cure Checker does not run, verify or endorse these organizations, and being listed is not a promise of help. Funds are limited and rules change, so confirm eligibility and details with each organization. Be careful of anyone who asks for payment up front or for your bank login to 'release' a grant.
Everything this report is based on, grouped by section. Checked October 2, 2026.
The CAG-repeat thresholds, juvenile-onset figures, the 1993 gene discovery, and the creatine, CoQ10 (2CARE) and ethyl-EPA trial results reflect the established published record. They don't yet have individual citations here. Financial help: checked October 6, 2026. The Huntington's Disease Association has no dedicated grants page, so its card is based on a story page that describes the scheme. Help 4 HD and Champions for HD publish no award amounts or detailed eligibility rules. HelpCureHD's 2026 cycle, the Scottish Short Breaks Fund and the HealthWell fund were closed that day. HDSA's only cash help found was convention scholarships, so it is not listed.